rhophilin associated tail protein 1 likeGenealiases: ASP · LINC01513 · RSPH11 · TCONS_00009352
Q-omics provides the consensus-scored ROPN1L profile across patient tissues and cancer cell-line models. ROPN1L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ROPN1L is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ROPN1L RNA expression shows 15,350 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KIRC, and ACC as cancer lineages where ROPN1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ROPN1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ROPN1L survival associations across molecular data types. ROPN1L RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ROPN1L RNA expression–survival associations across cancer types. High ROPN1L expression shows unfavorable associations in ACC, UVM, LGG, BLCA and KICH, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for ROPN1L RNA expression.
This table summarizes ROPN1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ROPN1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ROPN1L shows lower tumor expression in THCA, LUSC, LUAD and KICH and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher ROPN1L RNA expression in tumor versus normal tissue (log2 FC = +0.871, t-test p < 0.001).
This table shows molecular features associated with ROPN1L in patient tissues and cancer cell lines. In patient samples, ROPN1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ROPN1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and URINARY_TRACT.
